Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?

被引：0
|
作者：
Lieberman, Howard B. [1 ,2 ]
机构：
[1] Columbia Univ, Vagelos Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA
[2] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA
来源：
TRANSLATIONAL CANCER RESEARCH | 2020年 / 9卷 / 02期
关键词：
D O I：
10.21037/tcr.2019.12.102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：418 / 420
页数：3
相关论文
共 50 条
  • [21] MAINTENANCE TREATMENT WITH OLAPARIB IN BRCA-MUTATED HIGH GRADE SEROUS OVARIAN CANCER (HGSOC): OUR EXPERIENCE IN A CASE REPORT
    Mainella, A.
    Giacomi, N.
    Marmissolle, F.
    Vigo, S.
    Price, P.
    Sansano, M.
    Lujan, M. L.
    Zapata Caamano, G.
    Dominguez, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1585 - 1585
  • [22] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    Golan, Talia
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke C.
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen Mary
    McGuinness, David
    Cui Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [23] Olaparib Maintenance Therapy in BRCA-positive Ovarian Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03)
  • [24] Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
    Li, Na
    Zheng, Huanrui
    Huang, Yanlei
    Zheng, Bin
    Cai, Hongfu
    Liu, Maobai
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [25] Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
    Marme, F.
    Hilpert, F.
    Welslau, M.
    Grabowski, J. P.
    Schneeweiss, A.
    Hartkopf, A. D.
    Becker, S.
    Runnebaum, I.
    Bauerschlag, D.
    Fasching, P.
    Brandi, C.
    Rehbein, J-K.
    Glowik, R.
    Sehouli, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S535 - S536
  • [26] Overall survival in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance: Real-world data of the C-PATROL study
    Marme, Frederik
    Hilpert, Felix
    Welslau, Manfred
    Grabowski, Jacek P.
    Schneeweiss, Andreas
    Hartkopf, Andreas D.
    Bauerschlag, Dirk
    Fasching, Peter A.
    Brandi, Christiane
    Rehbein, John-Kilian
    Glowik, Regina
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context
    Gonzalez-Martin, Antonio
    Matulonis, Ursula A.
    Korach, Jacob
    Mirza, Mansoor R.
    Moore, Kathleen N.
    Wu, Xiaohua
    York, Whitney
    Gupta, Divya
    Lechpammer, Stanislav
    Monk, Bradley J.
    FUTURE ONCOLOGY, 2022, 18 (23) : 2505 - 2536
  • [28] Using chemotherapy response by KELIM score in patient with BRCA-mutated high-grade serous ovarian cancer to predict response to first line olaparib maintenance therapy: an one institution experience
    Katic, Kristina
    Matkovic, Visnja
    Lesin, Josko
    Planinic, Pavao
    Vujic, Goran
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A376 - A377
  • [29] Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
    Velev, Maud
    Puszkiel, Alicja
    Blanchet, Benoit
    de Percin, Sixtine
    Delanoy, Nicolas
    Medioni, Jacques
    Gervais, Claire
    Balakirouchenane, David
    Khoudour, Nihel
    Pautier, Patricia
    Leary, Alexandra
    Ajgal, Zahra
    Hirsch, Laure
    Goldwasser, Francois
    Alexandre, Jerome
    Beinse, Guillaume
    PHARMACEUTICALS, 2021, 14 (08)
  • [30] EFFICACY AND SAFETY OF MAINTENANCE OLAPARIB BY PATIENT AGE IN NON-GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER IN OPINION
    Skof, E.
    Bjurberg, M.
    Rubio Perez, M. J.
    Davidson, D.
    Blakeley, C.
    Bennett, J.
    Poveda, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A202 - A203
12345